oligopeptide - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	oligopeptide	go back to main search page
Accession:	CHEBI:25676	browse the term
Definition:	A peptide containing a relatively small number of amino acids.
Synonyms:	related_synonym:	Oligopeptid; oligopeptides; oligopeptido
	alt_id:	CHEBI:7755; MESH:D009842
	xref_mesh:	MESH:D009842
	xref:	Wikipedia:Oligopeptide

show annotations for term's descendants Sort by:
Rat (1350) Mouse (1350) Human (1354) Chinchilla (0) Bonobo (0) Dog (16) Squirrel (0) Pig (30) Green Monkey (0) Naked Mole-rat (0) All
Genes (1350)

oligopeptide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Oligopeptides analog results in decreased phosphorylation of AKT1 protein]; Acetylcysteine inhibits the reaction [Oligopeptides analog results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

autophagy related 12

decreases expression

Oligopeptides analog results in decreased expression of ATG12 protein

NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418

G

autophagy related 3

increases expression

Oligopeptides analog results in increased expression of ATG3 protein

NCBI chr11:55,624,914...55,653,249
Ensembl chr11:55,624,917...55,653,224

G

autophagy related 5

increases expression

Oligopeptides analog results in increased expression of ATG5 protein

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

increases expression

Oligopeptides analog results in increased expression of ATG7 protein

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

BCL2 associated X, apoptosis regulator

increases expression

Oligopeptides analog results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

Oligopeptides analog results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

beclin 1

multiple interactions
increases expression

BECN1 mutant form inhibits the reaction [Oligopeptides analog results in increased cleavage of PARP1 protein]
Oligopeptides analog results in increased expression of BECN1 protein

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

caspase 3

multiple interactions
increases cleavage

benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Oligopeptides analog results in increased cleavage of CASP3 protein]
Oligopeptides inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]

PMID:24875536 PMID:25868679

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Oligopeptides inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cathepsin S

decreases expression

Oligopeptides analog results in decreased expression of CTSS protein

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

C-X-C motif chemokine ligand 2

multiple interactions

Oligopeptides inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Oligopeptides inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

glutathione synthetase

increases activity

Oligopeptides results in increased activity of GSS protein

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

Oligopeptides analog results in increased phosphorylation of MAPK1 protein
U 0126 inhibits the reaction [Oligopeptides analog results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

Oligopeptides analog results in increased phosphorylation of MAPK3 protein
U 0126 inhibits the reaction [Oligopeptides analog results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mechanistic target of rapamycin kinase

decreases phosphorylation

Oligopeptides analog results in decreased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

nitric oxide synthase 2

multiple interactions

Oligopeptides inhibits the reaction [Galactose results in increased activity of NOS2 protein]; Oligopeptides inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]

PMID:22154906 PMID:23796539

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Oligopeptides analog results in increased cleavage of PARP1 protein]; 3-methyladenine inhibits the reaction [Oligopeptides analog results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [Oligopeptides analog results in increased cleavage of PARP1 protein]; BECN1 mutant form inhibits the reaction [Oligopeptides analog results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Oligopeptides analog results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Oligopeptides inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S6 kinase B1

decreases phosphorylation

Oligopeptides analog results in decreased phosphorylation of RPS6KB1 protein

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

tumor necrosis factor

multiple interactions

Oligopeptides inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Oligopeptides inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

[des-Arg(9)]-bradykinin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

bradykinin receptor B1

increases expression
multiple interactions

bradykinin, des-Arg(9)- results in increased expression of BDKRB1 protein
lipopolysaccharide A promotes the reaction [bradykinin, des-Arg(9)- results in increased expression of BDKRB1 protein]; Thalidomide inhibits the reaction [bradykinin, des-Arg(9)- results in increased expression of BDKRB1 protein]; TNF protein promotes the reaction [bradykinin, des-Arg(9)- results in increased expression of BDKRB1 protein]; TNFRSF1A protein promotes the reaction [bradykinin, des-Arg(9)- results in increased expression of BDKRB1 protein]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

tumor necrosis factor

multiple interactions

TNF protein promotes the reaction [bradykinin, des-Arg(9)- results in increased expression of BDKRB1 protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 1A

multiple interactions

TNFRSF1A protein promotes the reaction [bradykinin, des-Arg(9)- results in increased expression of BDKRB1 protein]

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

Ac-Asp-Glu

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

folate hydrolase 1

affects binding
multiple interactions

isospaglumic acid binds to FOLH1 protein
[2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [isospaglumic acid binds to FOLH1 protein]

NCBI chr 1:140,428,101...140,501,563
Ensembl chr 1:140,428,101...140,501,379

Ac-Ser-Asp-Lys-Pro-OH

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

increases expression
decreases expression
multiple interactions

goralatide results in increased expression of ACE mRNA
goralatide results in decreased expression of ACE mRNA
[BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA]

PMID:20096676 PMID:33007385

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

actin alpha 2, smooth muscle

multiple interactions

goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]

PMID:31181250 PMID:33007385

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

angiotensinogen

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein]

PMID:31181250 PMID:33007385

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein]

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

bradykinin receptor B1

multiple interactions
affects abundance

[BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide
BDKRB1 protein affects the abundance of goralatide

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

cadherin 1

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

collagen type III alpha 1 chain

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

GLI family zinc finger 1

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

GLI family zinc finger 2

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]

NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574

G

GLI family zinc finger 3

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]

NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein]

NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709

G

patched 1

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]

NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333

G

sonic hedgehog signaling molecule

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]

NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170

G

smoothened, frizzled class receptor

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein]

NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829

G

vimentin

multiple interactions

goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

acetylleucyl-leucyl-norleucinal

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

apolipoprotein B

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline results in decreased secretion of APOB protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [lactacystin results in decreased expression of and results in decreased secretion of APOB protein]; acetylleucyl-leucyl-norleucinal results in increased expression of and results in increased secretion of APOB protein

PMID:19342510 PMID:19383982

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

baculoviral IAP repeat-containing 5

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Immunologic Factors results in decreased expression of BIRC5 protein]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

calpain 1

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Acetaminophen results in increased expression of CAPN1 protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [Acrylamide results in increased expression of CAPN1 protein]

PMID:35713544 PMID:37353096

NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177

G

calpain 2

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Acetaminophen results in increased expression of CAPN2 protein]

NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969

G

caspase 3

increases activity
multiple interactions

acetylleucyl-leucyl-norleucinal results in increased activity of CASP3 protein
acetylleucyl-leucyl-norleucinal inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]

PMID:15618349 PMID:27481217 PMID:29111403

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions

acetylleucyl-leucyl-norleucinal promotes the reaction [Immunologic Factors results in increased expression of CASP7 protein modified form]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

calpastatin

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Acetaminophen results in increased cleavage of CAST protein]

NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659

G

cyclin B1

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [arsenite results in increased degradation of CCNB1 protein]

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [resveratrol results in increased degradation of CCND1 protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [Tretinoin results in increased degradation of and results in decreased expression of CCND1 protein]

PMID:11895924 PMID:16024653

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D3

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Tretinoin results in increased degradation of and results in decreased expression of CCND3 protein]

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cell division cycle 20

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Cadmium Chloride results in increased degradation of CDC20 protein]; acetylleucyl-leucyl-norleucinal promotes the reaction [Cadmium Chloride results in increased ubiquitination of CDC20 protein]

NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512

G

catenin beta 1

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Immunologic Factors results in decreased expression of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

dynamin 1-like

multiple interactions

acetylleucyl-leucyl-norleucinal affects the reaction [Acetaminophen affects the phosphorylation of DNM1L protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [Acetaminophen results in increased expression of and results in increased cleavage of DNM1L protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]

PMID:27481217 PMID:35713544

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

eukaryotic translation initiation factor 4E

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Cadmium Chloride results in decreased expression of EIF4E protein]

NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683

G

gap junction protein, alpha 1

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [arsenic trioxide results in decreased expression of GJA1 mRNA]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glutamic--pyruvic transaminase

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Acetaminophen results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

heat shock protein family A (Hsp70) member 9

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Acrylamide results in decreased expression of HSPA9 protein]

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

interleukin 1 beta

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [IL1B protein results in increased ubiquitination of NFKBIA protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

insulin 1

decreases secretion

acetylleucyl-leucyl-norleucinal results in decreased secretion of INS1 protein

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

integrin subunit alpha M

multiple interactions

acetylleucyl-leucyl-norleucinal promotes the reaction [Tretinoin results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

inositol 1,4,5-trisphosphate receptor, type 3

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Acrylamide results in decreased expression of ITPR3 protein]

NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases phosphorylation

acetylleucyl-leucyl-norleucinal results in increased phosphorylation of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

mitogen-activated protein kinase 8

increases phosphorylation

acetylleucyl-leucyl-norleucinal results in increased phosphorylation of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 8 interacting protein 1

increases expression

acetylleucyl-leucyl-norleucinal results in increased expression of MAPK8IP1 protein

NCBI chr 3:78,355,051...78,372,946
Ensembl chr 3:78,355,048...78,372,884

G

mitofusin 2

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Acetaminophen results in decreased expression of and results in increased cleavage of MFN2 protein]

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Immunologic Factors results in decreased expression of MYC protein]

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NFKB inhibitor alpha

multiple interactions
decreases degradation

acetylleucyl-leucyl-norleucinal inhibits the reaction [4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid results in increased degradation of and results in decreased expression of NFKBIA protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [IL1B protein results in increased ubiquitination of NFKBIA protein]
acetylleucyl-leucyl-norleucinal results in decreased degradation of NFKBIA protein

PMID:15930313 PMID:17291458 PMID:18606398

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

poly (ADP-ribose) polymerase 1

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

protein phosphatase 3 catalytic subunit alpha

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Acetaminophen results in increased cleavage of PPP3CA protein]

NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974

G

RAD51 recombinase

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]; acetylleucyl-leucyl-norleucinal inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

recombination signal binding protein for immunoglobulin kappa J region

increases expression

acetylleucyl-leucyl-norleucinal results in increased expression of RBPJ protein

NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353

G

sodium channel epithelial 1 subunit gamma

increases methylation
decreases expression

acetylleucyl-leucyl-norleucinal results in increased methylation of SCNN1G promoter
acetylleucyl-leucyl-norleucinal results in decreased expression of SCNN1G mRNA

NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816

G

solute carrier family 38, member 3

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [manganese chloride results in increased degradation of SLC38A3 protein]

NCBI chr 8:108,323,889...108,339,959
Ensembl chr 8:108,323,894...108,339,988

G

sterol regulatory element binding transcription factor 1

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [SGA 360 results in increased degradation of and results in decreased expression of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

titin

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [Doxorubicin results in increased degradation of TTN protein]

NCBI chr 3:61,652,432...61,924,912
Ensembl chr 3:61,652,439...61,924,741

G

thymidine phosphorylase

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMP protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]]

PMID:21444628 PMID:30796972

NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874

G

thymidylate synthetase

multiple interactions

acetylleucyl-leucyl-norleucinal inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein]

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

Ala-Gln

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 8

multiple interactions

alanylglutamine inhibits the reaction [tcdA protein, Clostridium difficile results in increased activity of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

Arg-Gly-Asp

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

arginyl-glycyl-aspartic acid inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

integrin subunit alpha 5

multiple interactions

arginyl-glycyl-aspartic acid inhibits the reaction [Resveratrol binds to [ITGA5 protein binds to ITGB3 protein]]

NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837

G

integrin subunit alpha V

multiple interactions

arginyl-glycyl-aspartic acid inhibits the reaction [manganese chloride affects the localization of and affects the activity of [ITGB3 protein binds to ITGAV protein]]

NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639

G

integrin subunit beta 1

affects binding

arginyl-glycyl-aspartic acid binds to ITGB1 protein

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

integrin subunit beta 3

multiple interactions

arginyl-glycyl-aspartic acid inhibits the reaction [manganese chloride affects the localization of and affects the activity of [ITGB3 protein binds to ITGAV protein]]; arginyl-glycyl-aspartic acid inhibits the reaction [Resveratrol binds to [ITGA5 protein binds to ITGB3 protein]]

PMID:15213856 PMID:16790523

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

mitogen activated protein kinase 1

multiple interactions

arginyl-glycyl-aspartic acid inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK1 protein]
arginyl-glycyl-aspartic acid inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein]; arginyl-glycyl-aspartic acid inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK1 protein]

PMID:14627993 PMID:16790523 PMID:17984113

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

arginyl-glycyl-aspartic acid inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK3 protein]
arginyl-glycyl-aspartic acid inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein]; arginyl-glycyl-aspartic acid inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK3 protein]

PMID:14627993 PMID:16790523 PMID:17984113

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 1

increases expression

arginyl-glycyl-aspartic acid results in increased expression of MMP1

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

myosin light chain 9

affects phosphorylation

arginyl-glycyl-aspartic acid affects the phosphorylation of MYL9 protein

NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333

G

POU class 5 homeobox 1

decreases expression

arginyl-glycyl-aspartic acid results in decreased expression of POU5F1 protein

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

transcription factor AP-2 alpha

decreases expression

arginyl-glycyl-aspartic acid results in decreased expression of TFAP2A protein

NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507

G

TIMP metallopeptidase inhibitor 1

decreases expression

arginyl-glycyl-aspartic acid results in decreased expression of TIMP1

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor protein p53

multiple interactions

arginyl-glycyl-aspartic acid inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

aspartame

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 4

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily D member 1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of ABCD1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCD1 mRNA

NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115

G

ATP binding cassette subfamily D member 2

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCD2 mRNA

NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642

G

acetyl-CoA acyltransferase 1A

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of ACAA1A mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACAA1A mRNA

NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624

G

acetyl-Coenzyme A acyltransferase 1B

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825

G

acetyl-CoA carboxylase beta

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

acyl-CoA dehydrogenase short chain

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of ACADS mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACADS mRNA

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

acyl-CoA dehydrogenase, very long chain

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of ACADVL mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACADVL mRNA

NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075

G

acetylcholinesterase

decreases activity

Aspartame metabolite results in decreased activity of ACHE protein

PMID:16129618 PMID:17580119 PMID:17673349

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

aconitase 1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of ACO1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACO1 mRNA

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

acyl-CoA thioesterase 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

adhesion G protein-coupled receptor E1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ADGRE1 mRNA

NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000

G

angiotensinogen

decreases expression

Aspartame results in decreased expression of AGT mRNA

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

decreases expression

Aspartame results in decreased expression of AGTR1 mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

AKT serine/threonine kinase 1

increases phosphorylation

Aspartame results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

arachidonate 15-lipoxygenase

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ALOX15 mRNA

NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874

G

apolipoprotein E

decreases expression

Aspartame results in decreased expression of APOE mRNA

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[Aspartame co-treated with Methotrexate] results in increased expression of BAX mRNA; [Aspartame co-treated with Methotrexate] results in increased expression of BAX protein
Aspartame results in increased expression of BAX mRNA
[Fats, Unsaturated co-treated with Aspartame] affects the expression of BAX mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of BAX mRNA

PMID:23783067 PMID:25009784 PMID:32951320

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

[Aspartame co-treated with Methotrexate] results in decreased expression of BCL2 mRNA; [Aspartame co-treated with Methotrexate] results in decreased expression of BCL2 protein
Aspartame results in decreased expression of BCL2 mRNA

PMID:25009784 PMID:32951320

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

calcium binding protein 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CABP2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CABP2 mRNA

NCBI chr 1:201,374,649...201,380,469
Ensembl chr 1:201,375,276...201,380,469

G

calcium voltage-gated channel subunit alpha1 A

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CACNA1A mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNA1A mRNA

NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225

G

calcium voltage-gated channel subunit alpha1 I

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CACNA1I mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNA1I mRNA

NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688

G

calcium voltage-gated channel auxiliary subunit alpha2delta 4

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CACNA2D4 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNA2D4 mRNA

NCBI chr 4:152,408,588...152,521,478
Ensembl chr 4:152,408,657...152,521,268

G

calcium voltage-gated channel auxiliary subunit beta 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CACNB2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNB2 mRNA

NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106

G

calcium voltage-gated channel auxiliary subunit gamma 4

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CACNG4 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNG4 mRNA

NCBI chr10:92,683,778...92,745,842
Ensembl chr10:92,683,761...92,746,126

G

calcium voltage-gated channel auxiliary subunit gamma 8

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CACNG8 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNG8 mRNA

NCBI chr 1:65,755,334...65,775,567
Ensembl chr 1:65,755,334...65,779,089

G

calcium homeostasis modulator family member 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CALHM2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CALHM2 mRNA

NCBI chr 1:246,022,324...246,028,050
Ensembl chr 1:246,022,324...246,028,218

G

calreticulin 3

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CALR3 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CALR3 mRNA

NCBI chr16:17,396,064...17,423,166
Ensembl chr16:17,396,247...17,423,015

G

calcium activated nucleotidase 1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CANT1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CANT1 mRNA

NCBI chr10:103,637,079...103,650,240
Ensembl chr10:103,531,504...103,650,109

G

caspase 3

multiple interactions
increases expression

[Aspartame co-treated with Methotrexate] results in increased expression of CASP3 mRNA; [Aspartame co-treated with Methotrexate] results in increased expression of CASP3 protein modified form
Aspartame results in increased expression of CASP3 mRNA

PMID:25009784 PMID:32951320

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CASP9 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CASP9 mRNA

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions
decreases activity

[Aspartame co-treated with Methotrexate] results in increased activity of CAT protein
Aspartame results in decreased activity of CAT protein

PMID:25009784 PMID:32951320

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] results in increased expression of CCL2 protein; [Sodium Glutamate co-treated with Aspartame] inhibits the reaction [Fats, Unsaturated results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cadherin 1

decreases expression

Aspartame results in decreased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cyclin-dependent kinase inhibitor 1A

affects localization
multiple interactions

Aspartame affects the localization of CDKN1A protein
TAS1R1 protein affects the reaction [Aspartame affects the localization of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
decreases expression

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CDKN1B mRNA
Aspartame results in decreased expression of CDKN1B protein

PMID:23783067 PMID:33992720

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

calcium homeostasis endoplasmic reticulum protein

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CHERP mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CHERP mRNA

NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507

G

C-x(9)-C motif containing 1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CMC1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CMC1 mRNA

NCBI chr 8:117,798,036...117,900,458
Ensembl chr 8:117,798,945...117,900,462

G

cytochrome c oxidase copper chaperone COX11

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of COX11 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of COX11 mRNA

NCBI chr10:75,458,735...75,465,322
Ensembl chr10:75,458,749...75,465,322

G

cytochrome c oxidase subunit 7A1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of COX7A1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of COX7A1 mRNA

NCBI chr 1:85,422,162...85,447,530
Ensembl chr 1:85,441,871...85,445,151

G

carnitine palmitoyltransferase 1B

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of CPT1B mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CPT1B mRNA

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

carnitine palmitoyltransferase 1c

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CPT1C mRNA

NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342

G

cAMP responsive element binding protein 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CREB1 mRNA

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

colony stimulating factor 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity

Aspartame results in increased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases activity

Aspartame results in increased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily b, polypeptide 1

multiple interactions

Aspartame results in increased expression of and results in increased activity of CYP2B1 protein

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases activity

Aspartame results in increased activity of CYP2B2 protein

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Aspartame results in increased expression of and results in increased activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 62

increases activity

Aspartame results in increased activity of CYP3A62 protein

NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833

G

diablo, IAP-binding mitochondrial protein

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of DIABLO mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of DIABLO mRNA

NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387

G

DnaJ heat shock protein family (Hsp40) member C27

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of DNAJC27 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of DNAJC27 mRNA

NCBI chr 6:27,068,713...27,098,449
Ensembl chr 6:27,068,686...27,098,449

G

E2F transcription factor 1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of E2F1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

endothelin 2

decreases expression

Aspartame results in decreased expression of EDN2 mRNA

NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814

G

endothelin receptor type A

decreases expression

Aspartame results in decreased expression of EDNRA mRNA

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of EHHADH mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

epoxide hydrolase 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of EPHX2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of EPHX2 mRNA

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

coagulation factor II, thrombin

decreases activity

Aspartame analog results in decreased activity of F2 protein; Aspartame results in decreased activity of F2 protein

NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486

G

fibroblast growth factor 1

increases expression

Aspartame results in increased expression of FGF1 mRNA

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

forkhead box O3

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of FOXO3 mRNA

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

follicle stimulating hormone subunit beta

decreases expression

Aspartame results in decreased expression of FSHB protein

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

GTP dependent ribosome recycling factor mitochondrial 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of GFM2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of GFM2 mRNA

NCBI chr 2:28,449,452...28,488,200
Ensembl chr 2:28,449,517...28,488,197

G

gastric inhibitory polypeptide

multiple interactions

Aspartame promotes the reaction [Fats, Unsaturated results in increased expression of GIP protein]; Sodium Glutamate inhibits the reaction [Aspartame promotes the reaction [Fats, Unsaturated results in increased expression of GIP protein]]

NCBI chr10:80,968,360...80,976,506
Ensembl chr10:80,968,352...80,976,503

G

GLI family zinc finger 1

affects localization
multiple interactions

Aspartame affects the localization of GLI1 protein
TAS1R1 protein affects the reaction [Aspartame affects the localization of GLI1 protein]

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

GLI family zinc finger 2

decreases expression

Aspartame results in decreased expression of GLI2 protein

NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574

G

glycogen synthase kinase 3 beta

increases phosphorylation

Aspartame results in increased phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions

[Aspartame co-treated with Methotrexate] results in decreased activity of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of HADHA mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of HADHA mRNA

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of HADHB mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of HADHB mRNA

NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869

G

histone deacetylase 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of HDAC1 mRNA

NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111

G

histone deacetylase 5

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of HDAC5 mRNA

NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235

G

hepatocyte growth factor

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of HGF mRNA

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

HRas proto-oncogene, GTPase

increases expression

Aspartame results in increased expression of HRAS

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

heparan sulfate proteoglycan 2

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of HSPG2 mRNA

NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of IDH2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of IDH2 mRNA

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 11

decreases expression

Aspartame results in decreased expression of IL11 mRNA

NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129

G

interleukin 1 beta

increases expression

Aspartame results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 3

decreases expression

Aspartame results in decreased expression of IL3 mRNA

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 6

increases secretion

Aspartame results in increased secretion of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inner membrane mitochondrial protein

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of IMMT mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of IMMT mRNA

NCBI chr 4:103,880,482...103,919,116
Ensembl chr 4:103,880,459...103,919,109

G

insulin 2

increases expression
multiple interactions

Aspartame results in increased expression of INS protein
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] results in increased expression of INS2 protein; Aspartame inhibits the reaction [Fats, Unsaturated results in increased expression of INS2 protein]

PMID:1805284 PMID:23783067

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

kinase insert domain receptor

increases secretion

Aspartame results in increased secretion of KDR protein

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

leptin

decreases expression
multiple interactions

Aspartame results in decreased expression of LEP protein
[Fats, Unsaturated co-treated with Aspartame] results in increased expression of LEP protein; [Sodium Glutamate co-treated with Aspartame] promotes the reaction [Fats, Unsaturated results in increased expression of LEP protein]

PMID:11890951 PMID:23783067

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

luteinizing hormone subunit beta

decreases expression

Aspartame results in decreased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

lipase G, endothelial type

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of LIPG mRNA

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

G

LDL receptor related protein 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of LRP1 mRNA

NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910

G

LDL receptor related protein 2

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of LRP2 mRNA

NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708

G

LDL receptor related protein 4

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of LRP4 mRNA

NCBI chr 3:77,429,600...77,483,593
Ensembl chr 3:77,429,798...77,483,593

G

mitogen activated protein kinase 1

increases phosphorylation

Aspartame results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation

Aspartame results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitochondrial calcium uniporter

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MCU mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MCU mRNA

NCBI chr20:27,417,529...27,580,110
Ensembl chr20:27,417,526...27,580,110

G

MDM2 proto-oncogene

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

mediator complex subunit 23

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MED23 mRNA

NCBI chr 1:20,490,315...20,558,461
Ensembl chr 1:20,490,315...20,537,463

G

myocyte enhancer factor 2D

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MEF2D mRNA

NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457

G

mitochondrial contact site and cristae organizing system subunit 10

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MINOS1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MINOS1 mRNA

NCBI chr 5:151,341,124...151,367,403
Ensembl chr 5:151,339,176...151,367,485

G

mitochondrial calcium uptake 1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MICU1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MICU1 mRNA

NCBI chr20:27,668,681...27,816,322
Ensembl chr20:27,668,747...27,814,964

G

mitochondrial ribosomal protein L20

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MRPL20 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MRPL20 mRNA

NCBI chr 5:166,408,962...166,413,492
Ensembl chr 5:166,408,962...166,413,492

G

mitochondrial ribosomal protein L3

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MRPL3 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MRPL3 mRNA

NCBI chr 8:105,670,184...105,693,544
Ensembl chr 8:105,670,184...105,693,544

G

mitochondrial ribosomal protein S12

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MRPS12 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MRPS12 mRNA

NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780

G

mitochondrial ribosomal protein S24

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MRPS24 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MRPS24 mRNA

NCBI chr14:80,584,671...80,588,801
Ensembl chr14:80,584,673...80,588,871

G

mitochondrial ribosomal protein S27

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MRPS27 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MRPS27 mRNA

NCBI chr 2:30,740,007...30,808,577
Ensembl chr 2:30,740,033...30,808,577

G

mitochondrial ribosomal protein S7

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MRPS7 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MRPS7 mRNA

NCBI chr10:100,843,691...100,846,838
Ensembl chr10:100,843,356...100,847,129

G

mitochondrial fission process 1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of MTFP1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of MTFP1 mRNA

NCBI chr14:78,968,434...78,972,274
Ensembl chr14:78,968,442...78,972,274

G

MYC proto-oncogene, bHLH transcription factor

increases expression

Aspartame results in increased expression of MYC
Aspartame results in increased expression of MYC protein

PMID:17354619 PMID:33992720

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

nuclear receptor co-repressor 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NCOR1 mRNA

NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032

G

NADH:ubiquinone oxidoreductase subunit A12

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of NDUFA12 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NDUFA12 mRNA

NCBI chr 7:28,771,330...28,798,316
Ensembl chr 7:28,771,330...28,798,315

G

NADH:ubiquinone oxidoreductase subunit A5

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of NDUFA5 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NDUFA5 mRNA

NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598

G

NADH:ubiquinone oxidoreductase subunit B10

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of NDUFB10 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NDUFB10 mRNA

NCBI chr10:13,749,273...13,751,434
Ensembl chr10:13,749,275...13,751,442

G

NADH:ubiquinone oxidoreductase subunit B2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of NDUFB2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NDUFB2 mRNA

NCBI chr 4:68,367,526...68,374,609
Ensembl chr15:46,536,062...46,536,851
Ensembl chr 4:46,536,062...46,536,851

G

NADH:ubiquinone oxidoreductase subunit B6

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of NDUFB6 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NDUFB6 mRNA

NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181

G

NADH:ubiquinone oxidoreductase core subunit S1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of NDUFS1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NDUFS1 mRNA

NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893

G

NADH:ubiquinone oxidoreductase subunit S6

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of NDUFS6 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NDUFS6 mRNA

NCBI chr 1:29,968,833...29,977,423
Ensembl chr 1:29,968,842...29,977,467

G

NADH:ubiquinone oxidoreductase core subunit V1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of NDUFV1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NDUFV1 mRNA

NCBI chr 1:201,300,365...201,305,461
Ensembl chr 1:201,299,985...201,305,466

G

neurofibromin 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NF1 mRNA

NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658

G

notch receptor 1

multiple interactions
affects localization

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NOTCH1 mRNA
Aspartame affects the localization of NOTCH1 protein modified form
TAS1R1 protein affects the reaction [Aspartame affects the localization of NOTCH1 protein modified form]

PMID:23783067 PMID:33992720

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

NADPH oxidase 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NOX1 mRNA

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

natriuretic peptide B

decreases expression

Aspartame results in decreased expression of NPPB mRNA

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

neuropeptide Y

decreases expression

Aspartame results in decreased expression of NPY protein

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of NR1I3 mRNA

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

one cut homeobox 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ONECUT1 mRNA

NCBI chr 8:75,599,432...75,633,598
Ensembl chr 8:75,599,740...75,627,277

G

pyruvate dehydrogenase E1 subunit alpha 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PDHA2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PDHA2 mRNA

NCBI chr 2:229,872,300...229,873,848

G

pyruvate dehydrogenase E1 subunit beta

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PDHB mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PDHB mRNA

NCBI chr15:16,752,561...16,758,503
Ensembl chr15:16,750,980...16,758,500

G

peroxisomal biogenesis factor 1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PEX1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PEX1 mRNA

NCBI chr 4:30,519,950...30,558,953
Ensembl chr 4:30,519,955...30,558,921

G

peroxisomal biogenesis factor 11 alpha

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PEX11A mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PEX11A mRNA

NCBI chr 1:133,680,091...133,687,172
Ensembl chr 1:133,680,091...133,687,172

G

peroxisomal biogenesis factor 13

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PEX13 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PEX13 mRNA

NCBI chr14:97,602,829...97,621,233
Ensembl chr14:97,603,539...97,621,262

G

peroxisomal biogenesis factor 5

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PEX5 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PEX5 mRNA

NCBI chr 4:157,270,671...157,296,432
Ensembl chr 4:157,270,672...157,296,431

G

peroxisomal biogenesis factor 7

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PEX7 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PEX7 mRNA

NCBI chr 1:14,582,698...14,646,686
Ensembl chr 1:14,582,699...14,646,748

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PFKFB2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PFKFB2 mRNA

NCBI chr13:42,147,473...42,174,699
Ensembl chr13:42,147,478...42,174,699

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PFKFB4 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PFKFB4 mRNA

NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634

G

phospholipase D2

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PLD2 mRNA

NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808

G

plasminogen

decreases expression

Aspartame results in decreased expression of PLG mRNA

NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786

G

plexin D1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PLXND1 mRNA

NCBI chr 4:149,002,786...149,043,097
Ensembl chr 4:149,002,784...149,043,244

G

DNA polymerase gamma, catalytic subunit

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of POLG mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of POLG mRNA

NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567

G

proopiomelanocortin

increases expression

Aspartame results in increased expression of POMC protein alternative form

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

POU class 5 homeobox 1

affects localization

Aspartame affects the localization of POU5F1 protein

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

peroxisome proliferator activated receptor alpha

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PPARA mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PPARD mRNA

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PPARGC1A mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

peroxiredoxin 5

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of PRDX5 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of PRDX5 mRNA

NCBI chr 1:204,099,826...204,103,589
Ensembl chr 1:204,099,826...204,114,268

G

Rho-associated coiled-coil containing protein kinase 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ROCK1 mRNA

NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571

G

S100 calcium binding protein A13

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of S100A13 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of S100A13 mRNA

NCBI chr 2:175,999,439...176,005,933

G

S100 calcium binding protein A8

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of S100A8 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

succinate dehydrogenase complex iron sulfur subunit B

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of SDHB mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of SDHB mRNA

NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293

G

sirtuin 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of SIRT1 mRNA

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sirtuin 2

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of SIRT2 mRNA

NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975

G

solute carrier family 15 member 1

decreases activity

Aspartame results in decreased activity of SLC15A1 protein

NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545

G

solute carrier family 4 member 2

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of SLC4A2 mRNA

NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965

G

solute carrier family 8 member A1

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of SLC8A1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of SLC8A1 mRNA

NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628

G

SRY-box transcription factor 2

affects localization

Aspartame affects the localization of SOX2 protein

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

sterol regulatory element binding transcription factor 2

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of SREBF2 mRNA

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

signal transducer and activator of transcription 3

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of STAT3 mRNA

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

SURF1, cytochrome c oxidase assembly factor

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of SURF1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of SURF1 mRNA

NCBI chr 3:10,241,793...10,244,686
Ensembl chr 3:10,241,837...10,263,315

G

taste 1 receptor member 1

increases expression
multiple interactions

Aspartame results in increased expression of TAS1R1 protein
Aspartame promotes the reaction [TAS1R3 protein binds to TAS1R1 protein]; TAS1R1 protein affects the reaction [Aspartame affects the localization of CDKN1A protein]; TAS1R1 protein affects the reaction [Aspartame affects the localization of GLI1 protein]; TAS1R1 protein affects the reaction [Aspartame affects the localization of NOTCH1 protein modified form]

NCBI chr 5:162,533,838...162,546,408
Ensembl chr 5:162,533,841...162,545,562

G

taste 1 receptor member 2

multiple interactions
affects binding

Aspartame binds to and results in increased activity of TAS1R2 protein; Aspartame promotes the reaction [TAS1R3 protein binds to TAS1R2 protein]; lactisole inhibits the reaction [Aspartame results in increased activity of [TAS1R3 protein binds to TAS1R2 protein]]
Aspartame binds to [TAS1R2 protein binds to TAS1R3 protein]; Aspartame binds to TAS1R2 protein

PMID:15353592 PMID:17168764 PMID:17935609 PMID:20173092 PMID:33992720

NCBI chr 5:151,909,617...151,925,760
Ensembl chr 5:151,830,701...151,925,345

G

taste 1 receptor member 3

affects binding
decreases expression
multiple interactions

Aspartame binds to [TAS1R2 protein binds to TAS1R3 protein]
Aspartame results in decreased expression of TAS1R3 protein
Aspartame promotes the reaction [TAS1R3 protein binds to TAS1R1 protein]; Aspartame promotes the reaction [TAS1R3 protein binds to TAS1R2 protein]; lactisole inhibits the reaction [Aspartame results in increased activity of [TAS1R3 protein binds to TAS1R2 protein]]

PMID:17168764 PMID:17935609 PMID:33992720

NCBI chr 5:166,468,703...166,472,759
Ensembl chr 5:166,469,589...166,472,742

G

transcription factor A, mitochondrial

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of TFAM mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of TFAM mRNA

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

thrombospondin 1

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of THBS1 mRNA

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

tumor necrosis factor

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] results in increased expression of TNF protein; [Sodium Glutamate co-treated with Aspartame] promotes the reaction [Fats, Unsaturated results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases expression
multiple interactions

Aspartame results in increased expression of TRP53; Aspartame results in increased expression of TRP53 mRNA
[Fats, Unsaturated co-treated with Aspartame] affects the expression of TRP53 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of TRP53 mRNA

PMID:17354619 PMID:23783067 PMID:32951320

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

transient receptor potential cation channel, subfamily V, member 1

increases activity

Aspartame results in increased activity of TRPV1 protein

PMID:17567713 PMID:18804451

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

Tu translation elongation factor, mitochondrial

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of TUFM mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of TUFM mRNA

NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395

G

uncoupling protein 2

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of UCP2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of UCP2 mRNA

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

ubiquinol-cytochrome c reductase, complex III subunit XI

multiple interactions

[Fats, Unsaturated co-treated with Aspartame] affects the expression of UQCR11 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of UQCR11 mRNA

NCBI chr 7:9,305,042...9,309,753
Ensembl chr 7:9,305,058...9,309,750

G

vascular endothelial growth factor A

increases secretion

Aspartame results in increased secretion of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

increases expression

Aspartame results in increased expression of VIM protein

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

xanthine dehydrogenase

multiple interactions

[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of XDH mRNA

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

atosiban

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cAMP responsive element binding protein 1

multiple interactions

atosiban inhibits the reaction [Sildenafil Citrate results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

B 581

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear factor kappa B subunit 1

decreases activity

B 581 results in decreased activity of NFKB1 protein

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

decreases phosphorylation

B 581 results in decreased phosphorylation of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

RELA proto-oncogene, NF-kB subunit

decreases activity

B 581 results in decreased activity of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

Belnacasan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 1

decreases activity
multiple interactions

belnacasan results in decreased activity of CASP1 protein
belnacasan inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of CASP1 protein]
belnacasan inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]

PMID:30205151 PMID:31070765 PMID:34935985

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

C-X-C motif chemokine ligand 1

multiple interactions

belnacasan inhibits the reaction [Clozapine results in increased secretion of CXCL1 protein]

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

interleukin 18

multiple interactions

belnacasan inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL18 protein]
belnacasan inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of IL18 protein]

PMID:30205151 PMID:31070765

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

belnacasan inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of IL1B protein]
belnacasan inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]
belnacasan inhibits the reaction [Clozapine results in increased secretion of IL1B protein]

PMID:30205151 PMID:31070765 PMID:34935985

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

tumor necrosis factor

multiple interactions

belnacasan inhibits the reaction [Clozapine results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

bradykinin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nitric oxide synthase 3

decreases expression

Bradykinin results in decreased expression of NOS3 mRNA

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

buserelin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 3

multiple interactions

[Buserelin co-treated with CGB3 protein] results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

AHNAK nucleoprotein 2

multiple interactions

[Buserelin co-treated with CGB3 protein] results in increased expression of AHNAK2 mRNA

NCBI chr 6:131,830,668...131,876,311

G

BCL2 associated X, apoptosis regulator

increases expression

Buserelin results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

caspase 3

increases expression

Buserelin results in increased expression of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases expression

Buserelin results in increased expression of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cytochrome c, somatic

affects localization

Buserelin affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

dickkopf WNT signaling pathway inhibitor 1

multiple interactions

[Buserelin co-treated with CGB3 protein] results in increased expression of DKK1 mRNA; [Buserelin co-treated with CGB3 protein] results in increased expression of DKK1 protein

NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202

G

dickkopf WNT signaling pathway inhibitor 2

multiple interactions

[Buserelin co-treated with CGB3 protein] results in decreased expression of DKK2 mRNA

NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:220,568,338...220,660,225

G

follicle stimulating hormone subunit beta

multiple interactions

Buserelin inhibits the reaction [Doxorubicin inhibits the reaction [FSHB protein results in increased chemical synthesis of Estradiol]]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

gonadotropin releasing hormone receptor

multiple interactions

Buserelin binds to and results in increased activity of GNRHR protein; Buserelin inhibits the reaction [GNRHR protein results in increased transport of deslorelin]

NCBI chr14:21,856,871...21,874,861
Ensembl chr14:21,856,871...21,874,861

G

mucin 16, cell surface associated

multiple interactions

[Buserelin co-treated with CGB3 protein] results in increased expression of MUC16 mRNA

NCBI chr 8:16,164,531...16,323,126

G

secreted frizzled-related protein 4

multiple interactions

[Buserelin co-treated with CGB3 protein] results in decreased expression of SFRP4 mRNA

NCBI chr17:45,278,867...45,330,806
Ensembl chr17:45,234,097...45,330,736

carfilzomib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-fetoprotein

multiple interactions

carfilzomib inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein]

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

androgen receptor

multiple interactions

carfilzomib inhibits the reaction [Metribolone results in increased activity of AR protein]

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

BRCA1, DNA repair associated

increases response to substance

BRCA1 mutant form results in increased susceptibility to carfilzomib

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

bromodomain containing 4

multiple interactions

carfilzomib inhibits the reaction [ARV-825 results in increased degradation of BRD4 protein]

NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539

G

basigin

multiple interactions
decreases expression

carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA]
carfilzomib results in decreased expression of BSG mRNA

NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387

G

caspase 3

increases cleavage
multiple interactions
increases activity

carfilzomib results in increased cleavage of CASP3 protein
apremilast inhibits the reaction [carfilzomib results in increased activity of CASP3 protein]

PMID:27769052 PMID:27785949

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

decreases activity

carfilzomib results in decreased activity of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

creatine kinase, M-type

increases secretion
multiple interactions

carfilzomib results in increased secretion of CKM protein
Dexrazoxane inhibits the reaction [carfilzomib results in increased secretion of CKM protein]
apremilast inhibits the reaction [carfilzomib results in increased secretion of CKM protein]

PMID:26899300 PMID:27785949

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

cytochrome c oxidase subunit 8A

decreases expression

carfilzomib results in decreased expression of COX8A mRNA

NCBI chr 1:204,402,118...204,404,439

G

C-X-C motif chemokine receptor 4

decreases expression
multiple interactions

carfilzomib results in decreased expression of CXCR4 mRNA
carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of CXCR4 mRNA]

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

estrogen receptor 1

multiple interactions

carfilzomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein]

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

carfilzomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein]

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

estrogen related receptor, alpha

multiple interactions

carfilzomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; carfilzomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]

NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268

G

glutamic-oxaloacetic transaminase 1

increases secretion
multiple interactions

carfilzomib results in increased secretion of GOT1 protein
apremilast inhibits the reaction [carfilzomib results in increased secretion of GOT1 protein]

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

multiple interactions

carfilzomib inhibits the reaction [Acetaminophen results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

lactate dehydrogenase A

multiple interactions
increases secretion

apremilast inhibits the reaction [carfilzomib results in increased secretion of LDHA protein]
Dexrazoxane inhibits the reaction [carfilzomib results in increased secretion of LDHA protein]

PMID:26899300 PMID:27785949

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

mitogen activated protein kinase 1

increases expression
multiple interactions

carfilzomib results in increased expression of MAPK1 mRNA
apremilast inhibits the reaction [carfilzomib results in increased expression of MAPK1 mRNA]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen-activated protein kinase 8

increases expression
multiple interactions

carfilzomib results in increased expression of MAPK8 mRNA
apremilast inhibits the reaction [carfilzomib results in increased expression of MAPK8 mRNA]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

matrix metallopeptidase 2

multiple interactions

carfilzomib inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

myosin heavy chain 6

multiple interactions
decreases expression

Dexrazoxane inhibits the reaction [carfilzomib results in decreased expression of MYH6 mRNA]

NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720

G

myosin heavy chain 7

increases expression
multiple interactions

carfilzomib results in increased expression of MYH7 mRNA
Dexrazoxane inhibits the reaction [carfilzomib results in increased expression of MYH7 mRNA]

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

NFE2 like bZIP transcription factor 2

increases activity

carfilzomib results in increased activity of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

multiple interactions
decreases expression

apremilast inhibits the reaction [carfilzomib results in decreased expression of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

carfilzomib inhibits the reaction [Acetaminophen results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

progesterone receptor

multiple interactions

carfilzomib inhibits the reaction [Promegestone results in increased activity of PGR protein]

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

PPARG coactivator 1 alpha

multiple interactions

carfilzomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

PRKCSH beta subunit of glucosidase II

increases response to substance

PRKCSH gene mutant form results in increased susceptibility to carfilzomib

NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492

G

prostaglandin-endoperoxide synthase 2

multiple interactions

carfilzomib inhibits the reaction [Acetaminophen results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

increases expression
multiple interactions

carfilzomib results in increased expression of RELA mRNA
apremilast inhibits the reaction [carfilzomib results in increased expression of RELA mRNA]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

transforming growth factor, beta 1

decreases activity

carfilzomib results in decreased activity of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

multiple interactions

carfilzomib inhibits the reaction [Diethylnitrosamine results in increased expression of TIMP1 protein]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions

carfilzomib inhibits the reaction [Acetaminophen results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases activity
affects activity

carfilzomib results in increased activity of TP53 protein
carfilzomib affects the activity of TP53 protein

PMID:30818834 PMID:35435491

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

zinc finger AN1-type containing 2A

increases expression

carfilzomib results in increased expression of ZFAND2A protein

NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677

carnosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Carnosine inhibits the reaction [cupric chloride results in decreased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

actin alpha 2, smooth muscle

multiple interactions

Carnosine inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

advanced glycosylation end product-specific receptor

multiple interactions

Carnosine inhibits the reaction [ALB protein modified form results in increased expression of AGER mRNA]; Carnosine inhibits the reaction [ALB protein modified form results in increased expression of AGER protein]

NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078

G

AKT serine/threonine kinase 1

multiple interactions

Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions

Carnosine inhibits the reaction [ALB protein modified form results in increased expression of AGER mRNA]; Carnosine inhibits the reaction [ALB protein modified form results in increased expression of AGER protein]; Carnosine inhibits the reaction [ALB protein modified form results in increased expression of COL3A1 mRNA]; Carnosine inhibits the reaction [ALB protein modified form results in increased expression of TNF mRNA]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

amyloid beta precursor protein

decreases expression

Carnosine results in decreased expression of APP protein modified form

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

BCL2 associated X, apoptosis regulator

multiple interactions

Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of BAX mRNA]; Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of BAX protein]
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased expression of BAX mRNA]; Carnosine inhibits the reaction [Glucose results in increased expression of BAX mRNA]

PMID:28266762 PMID:28833918 PMID:30802477

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

Carnosine inhibits the reaction [Sodium Nitrite results in decreased expression of BCL2 protein]
asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]; Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]

PMID:28266762 PMID:30802477

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

basic helix-loop-helix ARNT like 1

increases abundance

BMAL1 gene mutant form results in increased abundance of Carnosine

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

carnosine synthase 1

increases expression

Carnosine results in increased expression of CARNS1 mRNA; Carnosine results in increased expression of CARNS1 protein

NCBI chr 1:201,459,061...201,470,019
Ensembl chr 1:201,459,076...201,469,845

G

caspase 3

multiple interactions

Carnosine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Carnosine inhibits the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP3 protein]
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Carnosine inhibits the reaction [Glucose results in increased activity of CASP3 protein]
Carnosine inhibits the reaction [Sodium Nitrite results in increased activity of CASP3 protein]

PMID:19748544 PMID:28833918 PMID:29191451 PMID:30802477

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

Carnosine inhibits the reaction [Cisplatin results in increased cleavage of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

catalase

multiple interactions

Carnosine inhibits the reaction [Acetaminophen results in decreased activity of CAT protein]; Carnosine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Carnosine inhibits the reaction [Cisplatin results in decreased expression of CAT mRNA]
Carnosine inhibits the reaction [cupric chloride results in decreased activity of CAT protein]

PMID:19748544 PMID:19799668 PMID:29191451 PMID:32745495

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions

Carnosine inhibits the reaction [Acetaminophen results in increased expression of CCL2 mRNA]; Carnosine inhibits the reaction [Acetaminophen results in increased expression of CCL2 protein]; Carnosine inhibits the reaction [Cisplatin results in increased expression of CCL2 mRNA]

PMID:19799668 PMID:29191451

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

carnosine dipeptidase 1

increases expression

Carnosine results in increased expression of CNDP1 mRNA; Carnosine results in increased expression of CNDP1 protein

NCBI chr18:77,984,886...78,030,837
Ensembl chr18:77,984,907...78,007,765

G

collagen type III alpha 1 chain

multiple interactions

Carnosine inhibits the reaction [ALB protein modified form results in increased expression of COL3A1 mRNA]; Carnosine inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

C-reactive protein

multiple interactions

Carnosine inhibits the reaction [Acetaminophen results in increased expression of CRP protein]
Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of CRP protein]

PMID:19799668 PMID:28266762 PMID:28833918

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Carnosine inhibits the reaction [Acetaminophen results in increased activity of CYP2E1 protein]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Carnosine results in increased expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glucose-6-phosphate dehydrogenase

multiple interactions

Carnosine inhibits the reaction [cupric chloride results in decreased activity of G6PD protein]

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glutamic--pyruvic transaminase

multiple interactions

Carnosine inhibits the reaction [Sodium Nitrite results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

Carnosine inhibits the reaction [Acetaminophen results in decreased expression of GPX1 mRNA]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

multiple interactions

Carnosine inhibits the reaction [cupric chloride results in decreased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of HIF1A protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

heat shock protein family A (Hsp70) member 1B

increases expression

Carnosine results in increased expression of HSPA1B protein

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

intercellular adhesion molecule 1

multiple interactions

Carnosine inhibits the reaction [Cisplatin results in increased expression of ICAM1 mRNA]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

multiple interactions

Carnosine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

Carnosine inhibits the reaction [Acetaminophen results in increased expression of IL10 protein]; Carnosine inhibits the reaction [Cisplatin results in increased expression of IL10 mRNA]

PMID:19799668 PMID:29191451

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL1B protein]]; Carnosine inhibits the reaction [Streptozocin results in increased expression of IL1B protein]
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL1B protein]; Carnosine inhibits the reaction [Glucose results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL6 protein]]; Carnosine inhibits the reaction [Acetaminophen results in increased expression of IL6 protein]; Carnosine inhibits the reaction [Streptozocin results in increased expression of IL6 protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL6 protein]]
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Carnosine inhibits the reaction [Glucose results in increased secretion of IL6 protein]
Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of IL6 protein]

PMID:19799668 PMID:28266762 PMID:30802477

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

[Carnosine co-treated with asiatic acid] inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]; Carnosine inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

mitogen-activated protein kinase 8

multiple interactions

[Carnosine co-treated with asiatic acid] inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein]; Carnosine inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

myeloperoxidase

multiple interactions

Carnosine inhibits the reaction [Cadmium Chloride results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFKB inhibitor alpha

multiple interactions

Carnosine inhibits the reaction [Sodium Nitrite results in decreased expression of NFKBIA mRNA]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

Carnosine inhibits the reaction [Cisplatin results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

poly (ADP-ribose) polymerase 1

multiple interactions

Carnosine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

prostaglandin-endoperoxide synthase 2

multiple interactions

asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]]; Carnosine inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Carnosine inhibits the reaction [Cisplatin affects the localization of RELA protein]; Carnosine inhibits the reaction [Streptozocin results in increased expression of RELA protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]]

PMID:29191451 PMID:30802477

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

solute carrier family 15 member 2

increases expression

Carnosine results in increased expression of SLC15A2 mRNA; Carnosine results in increased expression of SLC15A2 protein

NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225

G

solute carrier family 15 member 4

increases expression

Carnosine results in increased expression of SLC15A4 mRNA

NCBI chr12:29,048,634...29,082,480
Ensembl chr12:29,063,015...29,082,480

G

solute carrier family 31 member 1

decreases expression

Carnosine results in decreased expression of SLC31A1 mRNA; Carnosine results in decreased expression of SLC31A1 protein

NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228

G

SMAD family member 2

multiple interactions

Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of SMAD2 protein]

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

superoxide dismutase 1

multiple interactions

Carnosine inhibits the reaction [cupric chloride results in decreased activity of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

Sp1 transcription factor

decreases expression

Carnosine results in decreased expression of SP1 mRNA

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

signal transducer and activator of transcription 3

multiple interactions

Carnosine inhibits the reaction [Norepinephrine results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

transforming growth factor, beta 1

multiple interactions

Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of TNF protein]]; Carnosine inhibits the reaction [Acetaminophen results in increased expression of TNF mRNA]; Carnosine inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; Carnosine inhibits the reaction [ALB protein modified form results in increased expression of TNF mRNA]; Carnosine inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]; Carnosine inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]]
asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in increased secretion of TNF protein]]; Carnosine inhibits the reaction [Glucose results in increased secretion of TNF protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]]
Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of TNF protein]

PMID:19799668 PMID:28266762 PMID:29191451 PMID:30802477 PMID:34609854

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

multiple interactions

Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

ceruletide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

PTHLH protein promotes the reaction [Ceruletide results in increased expression of ACTA2 protein]; Shuangshen inhibits the reaction [Ceruletide results in increased expression of ACTA2 mRNA]; Shuangshen inhibits the reaction [Ceruletide results in increased expression of ACTA2 protein]
Ceruletide results in increased expression of ACTA2 mRNA; Ceruletide results in increased expression of ACTA2 protein

PMID:25035110 PMID:38113986

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adenosylhomocysteinase

decreases expression

Ceruletide results in decreased expression of AHCY protein

NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393

G

aldo-keto reductase family 1 member B1

increases expression

Ceruletide results in increased expression of AKR1B1 protein

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

AKT serine/threonine kinase 1

multiple interactions

(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of AKT1 protein]; [KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

decreases expression

Ceruletide results in decreased expression of ALB protein modified form

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

activating transcription factor 4

multiple interactions

[2,2',4,4'-tetrabromodiphenyl ether co-treated with Ceruletide] results in increased expression of ATF4 protein

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

BCL2, apoptosis regulator

increases expression
multiple interactions

Ceruletide results in increased expression of BCL2 mRNA; Ceruletide results in increased expression of BCL2 protein
coumermycin inhibits the reaction [limonin inhibits the reaction [Ceruletide results in increased expression of BCL2 protein]]; limonin inhibits the reaction [Ceruletide results in increased expression of BCL2 mRNA]; limonin inhibits the reaction [Ceruletide results in increased expression of BCL2 protein]; Resveratrol inhibits the reaction [Ceruletide results in increased expression of BCL2 mRNA]; Resveratrol inhibits the reaction [Ceruletide results in increased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bradykinin receptor B1

increases expression

Ceruletide results in increased expression of BDKRB1 mRNA

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

bradykinin receptor B2

increases expression

Ceruletide results in increased expression of BDKRB2 mRNA

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

bromodomain containing 4

multiple interactions

(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of BRD4 protein]; [KRAS protein mutant form co-treated with Ceruletide] results in increased expression of BRD4 protein

NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539

G

caspase 3

multiple interactions

[Glycodeoxycholic Acid co-treated with Ceruletide] results in decreased activity of CASP3 protein; Ceruletide results in increased cleavage of and results in increased activity of CASP3 protein

PMID:16339139 PMID:18832452

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

Ceruletide results in increased cleavage of and results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

Ceruletide results in increased cleavage of and results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 2

multiple interactions
increases secretion
increases expression

coumermycin inhibits the reaction [limonin inhibits the reaction [Ceruletide results in increased secretion of CCL2 protein]]; limonin inhibits the reaction [Ceruletide results in increased secretion of CCL2 protein]; PPARG affects the reaction [Ceruletide results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [Ceruletide results in increased secretion of CCL2 protein]; Rosiglitazone inhibits the reaction [Ceruletide results in increased expression of CCL2 mRNA]

PMID:17463185 PMID:21484880 PMID:34423886

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin D1

multiple interactions
increases expression

coumermycin inhibits the reaction [limonin inhibits the reaction [Ceruletide results in increased expression of CCND1 protein]]; limonin inhibits the reaction [Ceruletide results in increased expression of CCND1 mRNA]; limonin inhibits the reaction [Ceruletide results in increased expression of CCND1 protein]; Resveratrol inhibits the reaction [Ceruletide results in increased expression of CCND1 mRNA]; Resveratrol inhibits the reaction [Ceruletide results in increased expression of CCND1 protein]
Ceruletide results in increased expression of CCND1 mRNA; Ceruletide results in increased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

chaperonin containing TCP1 subunit 2

increases expression

Ceruletide results in increased expression of CCT2 protein

NCBI chr 7:52,692,725...52,705,478
Ensembl chr 7:52,692,725...52,706,944

G

CCAAT/enhancer binding protein alpha

increases expression
multiple interactions

Ceruletide results in increased expression of CEBPA mRNA
[Dietary Fats co-treated with Ceruletide] results in increased expression of CEBPA protein; Dietary Fats promotes the reaction [Ceruletide results in increased expression of CEBPA mRNA]; Quercetin inhibits the reaction [[Dietary Fats co-treated with Ceruletide] results in increased expression of CEBPA protein]; Quercetin inhibits the reaction [Ceruletide results in increased expression of CEBPA mRNA]

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

multiple interactions
increases expression

[Dietary Fats co-treated with Ceruletide] results in increased expression of CEBPB protein; Dietary Fats promotes the reaction [Ceruletide results in increased expression of CEBPB mRNA]; Quercetin inhibits the reaction [[Dietary Fats co-treated with Ceruletide] results in increased expression of CEBPB protein]; Quercetin inhibits the reaction [Ceruletide results in increased expression of CEBPB mRNA]

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

collagen type I alpha 1 chain

multiple interactions
increases expression

PTHLH protein modified form inhibits the reaction [Ceruletide results in increased expression of COL1A1 mRNA]; PTHLH protein promotes the reaction [Ceruletide results in increased expression of COL1A1 mRNA]
PTHLH protein inhibits the reaction [Ceruletide results in increased expression of COL1A1 mRNA]

PMID:22280800 PMID:25035110

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

cathepsin B

affects localization
multiple interactions

Ceruletide affects the localization of CTSB protein
sodium arsenite inhibits the reaction [Ceruletide affects the localization of CTSB protein]

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

C-X-C motif chemokine ligand 3

increases expression
multiple interactions

Ceruletide results in increased expression of CXCL1 mRNA
AM 251 inhibits the reaction [Ceruletide results in increased expression of CXCL1 mRNA]; AM 251 promotes the reaction [iodopravadoline inhibits the reaction [Ceruletide results in increased expression of CXCL1 mRNA]]; HU 211 inhibits the reaction [Ceruletide results in increased expression of CXCL1 mRNA]; iodopravadoline inhibits the reaction [Ceruletide results in increased expression of CXCL1 mRNA]; iodopravadoline promotes the reaction [AM 251 inhibits the reaction [Ceruletide results in increased expression of CXCL1 mRNA]]; PPARG affects the reaction [Ceruletide results in increased expression of CXCL1 mRNA]

PMID:17463185 PMID:17484889

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

DNA-damage inducible transcript 3

multiple interactions

[2,2',4,4'-tetrabromodiphenyl ether co-treated with Ceruletide] results in increased expression of DDIT3 protein

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

dual specificity phosphatase 1

increases expression

Ceruletide results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 10

increases expression

Ceruletide results in increased expression of DUSP10 mRNA

NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716

G

dual specificity phosphatase 6

increases expression

Ceruletide results in increased expression of DUSP6 mRNA

NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

[2,2',4,4'-tetrabromodiphenyl ether co-treated with Ceruletide] results in increased expression of and results in increased phosphorylation of EIF2AK3 protein

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

endoplasmic reticulum to nucleus signaling 1

increases expression
multiple interactions

Ceruletide results in increased expression of ERN1 mRNA; Ceruletide results in increased expression of ERN1 protein
Dietary Fats promotes the reaction [Ceruletide results in increased expression of ERN1 mRNA]; Dietary Fats promotes the reaction [Ceruletide results in increased expression of ERN1 protein]; Quercetin inhibits the reaction [Ceruletide results in increased expression of ERN1 mRNA]; Quercetin inhibits the reaction [Ceruletide results in increased expression of ERN1 protein]

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

glutamate dehydrogenase 1

increases expression

Ceruletide results in increased expression of GLUD1 protein

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

glutamic--pyruvic transaminase

multiple interactions
increases expression

isoborneol inhibits the reaction [Ceruletide results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

heme oxygenase 1

increases expression
multiple interactions

Ceruletide results in increased expression of HMOX1 protein
coumermycin inhibits the reaction [limonin inhibits the reaction [Ceruletide results in increased expression of HMOX1 protein]]; limonin inhibits the reaction [Ceruletide results in increased expression of HMOX1 protein]; Resveratrol inhibits the reaction [Ceruletide results in increased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein H1

increases expression

Ceruletide results in increased expression of HNRNPH1 protein

NCBI chr10:34,692,868...34,702,849
Ensembl chr10:34,693,555...34,702,846

G

heat shock protein family A (Hsp70) member 5

decreases expression

Ceruletide results in decreased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

decreases expression

Ceruletide results in decreased expression of HSPA8 protein

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

hypoxia up-regulated 1

increases expression

Ceruletide results in increased expression of HYOU1 protein

NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186

G

intercellular adhesion molecule 1

multiple interactions
increases expression

PTHLH protein modified form inhibits the reaction [Ceruletide results in increased expression of ICAM1 mRNA]
rosiglitazone inhibits the reaction [Ceruletide results in increased expression of ICAM1 mRNA]

PMID:17463185 PMID:25035110

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 10

multiple interactions

[resveratrol co-treated with Ceruletide] results in increased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

increases expression
increases secretion
multiple interactions

Ceruletide results in increased expression of IL1B mRNA; Ceruletide results in increased expression of IL1B protein
Ceruletide results in increased secretion of IL1B protein
coumermycin inhibits the reaction [limonin inhibits the reaction [Ceruletide results in increased secretion of IL1B protein]]; isoborneol inhibits the reaction [Ceruletide results in increased expression of IL1B protein]; limonin inhibits the reaction [Ceruletide results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [Ceruletide results in increased secretion of IL1B protein]
Dietary Fats promotes the reaction [Ceruletide results in increased expression of IL1B mRNA]; Dietary Fats promotes the reaction [Ceruletide results in increased secretion of IL1B protein]; Quercetin inhibits the reaction [Ceruletide results in increased expression of IL1B mRNA]; Quercetin inhibits the reaction [Dietary Fats promotes the reaction [Ceruletide results in increased expression of IL1B mRNA]]; resveratrol inhibits the reaction [Ceruletide results in increased expression of IL1B protein]

PMID:14751415 PMID:21484880 PMID:24234420 PMID:26873426 PMID:33166053 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases expression
increases secretion
multiple interactions

Ceruletide results in increased expression of IL6 mRNA
Ceruletide results in increased secretion of IL6 protein
Dietary Fats promotes the reaction [Ceruletide results in increased expression of IL6 mRNA]; Dietary Fats promotes the reaction [Ceruletide results in increased secretion of IL6 protein]; PTHLH protein inhibits the reaction [Ceruletide results in increased expression of IL6 mRNA]; Quercetin inhibits the reaction [Ceruletide results in increased expression of IL6 mRNA]; Quercetin inhibits the reaction [Dietary Fats promotes the reaction [Ceruletide results in increased expression of IL6 mRNA]]
(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of IL6 protein]; [KRAS protein mutant form co-treated with Ceruletide] results in increased expression of IL6 protein; coumermycin inhibits the reaction [limonin inhibits the reaction [Ceruletide results in increased secretion of IL6 protein]]; HU 211 inhibits the reaction [Ceruletide results in increased expression of IL6 protein]; IL6 protein inhibits the reaction [(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein]]; isoborneol inhibits the reaction [Ceruletide results in increased expression of IL6 protein]; limonin inhibits the reaction [Ceruletide results in increased secretion of IL6 protein]; PTHLH protein promotes the reaction [Ceruletide results in increased expression of IL6 mRNA]; Resveratrol inhibits the reaction [Ceruletide results in increased secretion of IL6 protein]; Shuangshen inhibits the reaction [Ceruletide results in increased expression of IL6 protein]
Ceruletide results in increased expression of IL6 mRNA; Ceruletide results in increased expression of IL6 protein
PTHLH protein modified form inhibits the reaction [Ceruletide results in increased expression of IL6 mRNA]; PTHLH protein promotes the reaction [Ceruletide results in increased expression of IL6 mRNA]

PMID:17484889 PMID:22280800 PMID:25035110 PMID:26390243 PMID:26873426 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Janus kinase 2

multiple interactions
increases expression

coumermycin inhibits the reaction [limonin inhibits the reaction [Ceruletide results in increased expression of JAK2 protein]]; limonin inhibits the reaction [Ceruletide results in increased expression of JAK2 protein]; Resveratrol inhibits the reaction [Ceruletide results in increased expression of JAK2 protein]

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

Ceruletide results in increased expression of JUN mRNA
rosiglitazone inhibits the reaction [Ceruletide results in increased expression of JUN mRNA]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

KRAS proto-oncogene, GTPase

multiple interactions

(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of BRD4 protein]; (+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of IL6 protein]; (+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of AKT1 protein]; (+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein]; [KRAS protein mutant form co-treated with Ceruletide] results in increased expression of BRD4 protein; [KRAS protein mutant form co-treated with Ceruletide] results in increased expression of IL6 protein; [KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of AKT1 protein; [KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein; IL6 protein inhibits the reaction [(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein]]

NCBI chr 4:178,185,418...178,218,484

G

mitogen-activated protein kinase 8

multiple interactions

[2,2',4,4'-tetrabromodiphenyl ether co-treated with Ceruletide] results in increased expression of and results in increased phosphorylation of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

microRNA 216a

increases expression

Ceruletide results in increased expression of MIR216A mRNA

NCBI chr14:102,524,105...102,524,210
Ensembl chr14:102,524,105...102,524,210

G

microRNA 216b

increases expression

Ceruletide results in increased expression of MIR216B mRNA

NCBI chr14:102,513,054...102,513,155
Ensembl chr14:102,513,054...102,513,155

G

microRNA 217

increases expression

Ceruletide results in increased expression of MIR217 mRNA

NCBI chr14:102,531,505...102,531,609
Ensembl chr14:102,531,505...102,531,609

G

myeloperoxidase

increases expression
increases activity
multiple interactions

Ceruletide results in increased expression of MPO protein
Ceruletide results in increased activity of MPO protein
HU 211 inhibits the reaction [Ceruletide results in increased expression of MPO protein]; isoborneol inhibits the reaction [Ceruletide results in increased activity of MPO protein]

PMID:17484889 PMID:33166053

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases expression

isoborneol inhibits the reaction [Ceruletide results in decreased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

increases degradation
multiple interactions

Ceruletide results in increased degradation of NFKBIA protein
sodium arsenite inhibits the reaction [Ceruletide results in increased degradation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

increases expression
multiple interactions

Ceruletide results in increased expression of NOS2 protein
isoborneol inhibits the reaction [Ceruletide results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

protein disulfide isomerase family A, member 4

increases expression

Ceruletide results in increased expression of PDIA4 protein

NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107

G

peroxisome proliferator-activated receptor gamma

multiple interactions

PPARG affects the reaction [Ceruletide results in increased expression of CCL2 mRNA]; PPARG affects the reaction [Ceruletide results in increased expression of CXCL1 mRNA]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

peroxiredoxin 2

increases expression

Ceruletide results in increased expression of PRDX2 protein

NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194

G

prostaglandin-endoperoxide synthase 2

increases expression

Ceruletide results in increased expression of PTGS2 mRNA; Ceruletide results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

parathyroid hormone-like hormone

multiple interactions
affects response to substance
increases expression

PTHLH protein modified form inhibits the reaction [Ceruletide results in increased expression of COL1A1 mRNA]; PTHLH protein modified form inhibits the reaction [Ceruletide results in increased expression of ICAM1 mRNA]; PTHLH protein modified form inhibits the reaction [Ceruletide results in increased expression of IL6 mRNA]; PTHLH protein promotes the reaction [Ceruletide results in increased expression of COL1A1 mRNA]; PTHLH protein promotes the reaction [Ceruletide results in increased expression of IL6 mRNA]
Ethanol results in increased susceptibility to [Ceruletide results in increased expression of PTHLH mRNA]; PTHLH protein inhibits the reaction [Ceruletide results in increased expression of COL1A1 mRNA]; PTHLH protein inhibits the reaction [Ceruletide results in increased expression of IL6 mRNA]
PTHLH protein affects the susceptibility to Ceruletide
Ceruletide results in increased expression of PTHLH mRNA; Ceruletide results in increased expression of PTHLH protein
PTHLH protein promotes the reaction [Ceruletide results in increased expression of ACTA2 protein]; PTHLH protein promotes the reaction [Ceruletide results in increased expression of COL1A1 mRNA]; PTHLH protein promotes the reaction [Ceruletide results in increased expression of IL6 mRNA]

PMID:22280800 PMID:25035110

NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
decreases phosphorylation
increases expression

ent-1,3,6,11-tetrahydroxykaur-16-ene-15-one 3,11-diacetate inhibits the reaction [Ceruletide results in increased expression of RELA protein]; isoborneol inhibits the reaction [Ceruletide results in decreased phosphorylation of RELA protein]

PMID:22982818 PMID:33166053

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

receptor interacting serine/threonine kinase 1

increases cleavage

Ceruletide results in increased cleavage of RIPK1 protein

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

RuvB-like AAA ATPase 1

increases expression

Ceruletide results in increased expression of RUVBL1 protein

NCBI chr 4:120,932,486...120,967,400
Ensembl chr 4:120,932,417...121,029,384

G

serpin family F member 1

increases activity

cerulein increases activity of Serpinf1 protein in blood

RGD

NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646

G

SMAD family member 2

multiple interactions

[Shuangshen co-treated with Ceruletide] results in decreased expression of SMAD2 protein

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

SMAD family member 3

increases expression
multiple interactions

Ceruletide results in increased expression of SMAD3 protein
Shuangshen inhibits the reaction [Ceruletide results in increased expression of SMAD3 protein]

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

superoxide dismutase 1

multiple interactions
decreases expression

isoborneol inhibits the reaction [Ceruletide results in decreased expression of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation

(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein]; [KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein; coumermycin inhibits the reaction [limonin inhibits the reaction [Ceruletide results in increased phosphorylation of STAT3 protein]]; IL6 protein inhibits the reaction [(+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased phosphorylation of STAT3 protein]]; limonin inhibits the reaction [Ceruletide results in increased phosphorylation of STAT3 protein]; Resveratrol inhibits the reaction [Ceruletide results in increased phosphorylation of STAT3 protein]

PMID:26390243 PMID:34423886

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

transforming growth factor, beta 1

multiple interactions
increases expression

Shuangshen inhibits the reaction [Ceruletide results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

increases expression
increases secretion
multiple interactions

Ceruletide results in increased expression of TNF mRNA; Ceruletide results in increased expression of TNF protein
Ceruletide results in increased secretion of TNF protein
coumermycin inhibits the reaction [limonin inhibits the reaction [Ceruletide results in increased secretion of TNF protein]]; isoborneol inhibits the reaction [Ceruletide results in increased expression of TNF protein]; limonin inhibits the reaction [Ceruletide results in increased secretion of TNF protein]; Resveratrol inhibits the reaction [Ceruletide results in increased secretion of TNF protein]; Shuangshen inhibits the reaction [Ceruletide results in increased expression of TNF protein]
2-acetoxy-5-(2-4-(trifluoromethyl)phenethylamino)benzoic acid inhibits the reaction [[Ceruletide co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; [Ceruletide co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA; arsenic trioxide inhibits the reaction [Ceruletide results in increased expression of TNF mRNA]; Dietary Fats promotes the reaction [Ceruletide results in increased expression of TNF mRNA]; Dietary Fats promotes the reaction [Ceruletide results in increased secretion of TNF protein]; Pentoxifylline inhibits the reaction [Ceruletide results in increased expression of TNF protein]; Quercetin inhibits the reaction [Ceruletide results in increased expression of TNF mRNA]; Quercetin inhibits the reaction [Dietary Fats promotes the reaction [Ceruletide results in increased expression of TNF mRNA]]

PMID:10773043 PMID:17517186 PMID:22575522 PMID:26873426 PMID:33166053 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

triosephosphate isomerase 1

increases expression

Ceruletide results in increased expression of TPI1 protein

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

valosin-containing protein

decreases expression

Ceruletide results in decreased expression of VCP protein

NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571

G

X-box binding protein 1

increases expression
multiple interactions

Ceruletide results in increased expression of XBP1 mRNA alternative form; Ceruletide results in increased expression of XBP1 protein alternative form
Dietary Fats promotes the reaction [Ceruletide results in increased expression of XBP1 mRNA alternative form]; Dietary Fats promotes the reaction [Ceruletide results in increased expression of XBP1 protein alternative form]; Quercetin inhibits the reaction [Ceruletide results in increased expression of XBP1 mRNA alternative form]; Quercetin inhibits the reaction [Ceruletide results in increased expression of XBP1 protein alternative form]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

X-linked inhibitor of apoptosis

increases degradation

Ceruletide results in increased degradation of XIAP protein

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

cetrorelix

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

cetrorelix results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

apolipoprotein E

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of APOE mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of APOE mRNA

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

BCL2 associated X, apoptosis regulator

increases expression

cetrorelix results in increased expression of BAX mRNA; cetrorelix results in increased expression of BAX protein

PMID:17268770 PMID:18829022

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

cetrorelix results in decreased expression of BCL2 protein
cetrorelix results in decreased expression of BCL2 mRNA

PMID:18829022 PMID:21062912

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

cetrorelix results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

caspase 3

increases activity

cetrorelix results in increased activity of CASP3 protein

PMID:17268770 PMID:21062912

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

cetrorelix results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cellular communication network factor 5

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of CCN5 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of CCN5 mRNA

NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636

G

cyclin-dependent kinase inhibitor 1A

increases expression

cetrorelix results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

chromogranin A

multiple interactions

[cetrorelix co-treated with testosterone enanthate] results in decreased expression of CHGA mRNA

NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398

G

cardiotrophin-like cytokine factor 1

decreases expression

cetrorelix results in decreased expression of CLCF1 mRNA

NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605

G

cystatin 9-like

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in increased expression of CST9L mRNA; [cetrorelix co-treated with testosterone enanthate] results in increased expression of CST9L mRNA

NCBI chr 3:136,288,093...136,290,906
Ensembl chr 3:136,288,093...136,290,906

G

C-X-C motif chemokine ligand 12

decreases expression

cetrorelix results in decreased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome b5 type A

multiple interactions

[cetrorelix co-treated with testosterone enanthate] results in decreased expression of CYB5A mRNA

NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of CYP11A1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of CYP11A1 mRNA

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of CYP17A1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of CYP17A1 mRNA

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

discoidin domain receptor tyrosine kinase 1

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in increased expression of DDR1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in increased expression of DDR1 mRNA

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

G

24-dehydrocholesterol reductase

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of DHCR24 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

dipeptidase 3

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of DPEP3 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of DPEP3 mRNA

NCBI chr19:33,868,229...33,876,609
Ensembl chr19:33,868,242...33,873,896

G

Fas cell surface death receptor

increases expression

cetrorelix results in increased expression of FAS mRNA; cetrorelix results in increased expression of FAS protein

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

follicle stimulating hormone subunit beta

decreases expression

cetrorelix results in decreased expression of FSHB protein

PMID:10077358 PMID:17638707

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

glutathione S-transferase alpha 2

multiple interactions

[cetrorelix co-treated with testosterone enanthate] results in decreased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

hypocretin receptor 1

decreases expression

cetrorelix results in decreased expression of HCRTR1 mRNA

NCBI chr 5:142,477,214...142,486,674
Ensembl chr 5:142,477,214...142,486,674

G

hypocretin receptor 2

decreases expression

cetrorelix results in decreased expression of HCRTR2 mRNA

NCBI chr 8:76,989,834...77,105,953
Ensembl chr 8:76,989,834...77,105,893

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of HMGCS2 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

hydroxysteroid (17-beta) dehydrogenase 6

multiple interactions

[cetrorelix co-treated with testosterone enanthate] results in decreased expression of HSD17B6 mRNA

NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425

G

insulin-like growth factor 1

decreases expression

cetrorelix results in decreased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 6

decreases expression

cetrorelix results in decreased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin-like 3

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of INSL3 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of INSL3 mRNA

NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560

G

luteinizing hormone subunit beta

decreases expression
multiple interactions
decreases secretion

cetrorelix results in decreased expression of LHB protein
cypermethrin inhibits the reaction [cetrorelix results in decreased secretion of LHB protein]

PMID:10077358 PMID:16914592 PMID:17638707 PMID:28731686

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

mitogen activated protein kinase 1

decreases phosphorylation

cetrorelix results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation

cetrorelix results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

methylsterol monooxygenase 1

multiple interactions

[cetrorelix co-treated with testosterone enanthate] results in decreased expression of MSMO1 mRNA

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

3'-phosphoadenosine 5'-phosphosulfate synthase 2

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of PAPSS2 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of PAPSS2 mRNA

NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331

G

progesterone receptor membrane component 1

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of PGRMC1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of PGRMC1 mRNA

NCBI chr X:115,832,865...115,841,060
Ensembl chr X:115,832,884...115,888,682

G

prolactin

decreases expression

cetrorelix results in decreased expression of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

prokineticin 1

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of PROK1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of PROK1 mRNA

NCBI chr 2:194,850,539...194,859,343
Ensembl chr 2:194,853,991...194,859,250

G

phosphoribosyl pyrophosphate synthetase 2

multiple interactions

[cetrorelix co-treated with testosterone enanthate] results in decreased expression of PRPS2 mRNA

NCBI chr X:26,975,915...27,013,184
Ensembl chr X:26,976,061...27,013,181

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

cetrorelix results in decreased phosphorylation of and results in decreased activity of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ras homolog family member B

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of RHOB mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of RHOB mRNA

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

steroidogenic acute regulatory protein

multiple interactions

[cetrorelix co-treated with testosterone enanthate] results in decreased expression of STAR mRNA

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 3

decreases phosphorylation

cetrorelix results in decreased phosphorylation of STAT3 protein

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

synaptonemal complex protein 1

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of SYCP1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of SYCP1 mRNA

NCBI chr 2:190,296,688...190,456,687
Ensembl chr 2:190,296,954...190,456,737

G

TATA-box binding protein associated factor 4b

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of TAF4B mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of TAF4B mRNA

NCBI chr18:5,952,737...6,086,408
Ensembl chr18:5,952,769...6,068,307

G

testis expressed gene 19.2

multiple interactions

[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of TEX19 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of TEX19 mRNA

NCBI chr10:106,379,757...106,382,344
Ensembl chr10:106,379,757...106,382,344

G

transforming growth factor, beta 1

decreases expression

cetrorelix results in decreased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TNF superfamily member 13

decreases expression

cetrorelix results in decreased expression of TNFSF13 mRNA

NCBI chr10:54,400,054...54,403,723
Ensembl chr10:54,400,065...54,403,042

G

tumor protein p53

increases expression

cetrorelix results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

vascular endothelial growth factor A

decreases expression

cetrorelix results in decreased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

CGP-42112A

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions

CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 2

multiple interactions

CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]]
[CGP 42112A binds to and results in increased activity of AGTR2 protein] which affects the susceptibility to Phenylephrine; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of and results in increased secretion of Triglycerides; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of Fatty Acids, Nonesterified; CGP 42112A binds to and results in increased activity of AGTR2 protein

PMID:16003179 PMID:19151255 PMID:25446015

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

angiotensin II receptor-associated protein

multiple interactions

CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]]

NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036

G

cytochrome b-245 beta chain

multiple interactions

CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

NADPH oxidase 1

multiple interactions

CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]]

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

NADPH oxidase 4

multiple interactions

CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]]

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

ubiquitin conjugating enzyme E2 V2

increases expression

CGP 42112A results in increased expression of UBE2V2 mRNA; CGP 42112A results in increased expression of UBE2V2 protein

NCBI chr11:85,304,528...85,338,430
Ensembl chr11:85,304,526...85,336,369

Chlamydocin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cyclin-dependent kinase inhibitor 1A

increases expression

chlamydocin analog results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

histone deacetylase 1

decreases activity

chlamydocin analog results in decreased activity of HDAC1 protein

NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111

G

histone deacetylase 4

decreases activity

chlamydocin analog results in decreased activity of HDAC4 protein

NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164

G

histone deacetylase 6

decreases activity

chlamydocin analog results in decreased activity of HDAC6 protein

NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441

DAPT

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions

1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

AKT serine/threonine kinase 1

multiple interactions

1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased secretion of APP protein modified form]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of BAX protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of BAX protein]]

PMID:21209419 PMID:34897970

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of BCL2 protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein]]

PMID:21209419 PMID:34897970

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 6

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA]

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

caspase 3

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein modified form]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of and results in increased activity of CASP3 protein

PMID:21209419 PMID:34897970

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP9 protein modified form]]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin D1

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of CCND1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cadherin 1

multiple interactions

[N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester co-treated with 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one] inhibits the reaction [polyhexamethyleneguanidine results in decreased expression of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased secretion of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased cleavage of CDH1 protein]

PMID:18791180 PMID:31348943

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of CDH2 protein]

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

colony stimulating factor 1

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of CSF1 mRNA]

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

enolase 2

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of ENO2 mRNA]

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

Fms related receptor tyrosine kinase 1

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of FLT1 protein]

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

forkhead box O3

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein]

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

hes family bHLH transcription factor 1

multiple interactions
decreases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased expression of HES1 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of HES1 protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HES1 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 protein]

PMID:19160421 PMID:24223152 PMID:25005833 PMID:25108166 PMID:32041402 More...

NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192

G

hes-related family bHLH transcription factor with YRPW motif 1

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA]

NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312

G

hes-related family bHLH transcription factor with YRPW motif 2

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HEY2 mRNA]

PMID:19160421 PMID:32041402

NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group box 1

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

interleukin 10

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL10 mRNA]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Diethylhexyl Phthalate results in increased expression of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA]

PMID:21843347 PMID:24223152 PMID:36988346

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL6 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]

PMID:21843347 PMID:24223152

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha M

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

involucrin

decreases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL protein

NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100

G

jagged canonical Notch ligand 1

decreases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 protein

NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209

G

keratin 1

multiple interactions
decreases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT1 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT1 mRNA

PMID:18633435 PMID:23566955

NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844

G

keratin 10

multiple interactions
decreases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT10 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 protein

PMID:18633435 PMID:23566955

NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701

G

leucine rich repeat containing G protein coupled receptor 5

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of LGR5 mRNA]

NCBI chr 7:51,087,059...51,221,882
Ensembl chr 7:51,088,239...51,222,446

G

microtubule-associated protein 2

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of MAP2 mRNA]

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

MDM2 proto-oncogene

multiple interactions
increases expression

Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein]

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

microRNA 141

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of BAX protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein modified form]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP9 protein modified form]]

NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332

G

MYD88, innate immune signal transduction adaptor

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 mRNA]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

nitric oxide synthase 2

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

notch receptor 1

multiple interactions
decreases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [phenethyl isothiocyanate results in increased cleavage of and results in increased activity of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH1 protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NOTCH1 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of NOTCH1 protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Oxygen deficiency results in increased expression of NOTCH1 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein modified form

PMID:18633435 PMID:22039516 PMID:22115781 PMID:24223152 PMID:25108166 More...

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

notch receptor 2

multiple interactions
decreases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH2 protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NOTCH2 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH2 protein

PMID:22039516 PMID:36988346

NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088

G

notch receptor 3

decreases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH3 protein

NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025

G

notch receptor 4

decreases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH4 protein

NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465

G

NUMB, endocytic adaptor protein

increases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of NUMB protein

NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354

G

PML nuclear body scaffold

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]]

NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971

G

peroxisome proliferator activated receptor alpha

increases expression
multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of PPARA protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of PPARA protein]

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 2

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

retinoic acid receptor, alpha

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]]

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

recombination signal binding protein for immunoglobulin kappa J region

multiple interactions
increases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RBPJ mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of RBPJ protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein]

PMID:22302987 PMID:24223152

NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of RELA protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

transforming growth factor, beta 1

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 4

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

decreases expression
multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein
Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TNF receptor associated factor 6

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 mRNA]

NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507

G

tubulin, beta 3 class III

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of TUBB3 mRNA]

NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243

G

vascular endothelial growth factor A

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

villin 1

multiple interactions

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of VIL1 mRNA]

NCBI chr 9:75,991,141...76,018,860
Ensembl chr 9:75,991,141...76,018,858

Deslorelin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gonadotropin releasing hormone receptor

increases transport
multiple interactions

GNRHR protein results in increased transport of deslorelin
2,4-Dinitrophenol inhibits the reaction [GNRHR protein results in increased transport of deslorelin]; Buserelin inhibits the reaction [GNRHR protein results in increased transport of deslorelin]

NCBI chr14:21,856,871...21,874,861
Ensembl chr14:21,856,871...21,874,861

DSLET

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

opioid receptor, delta 1

multiple interactions
affects binding

Cadmium inhibits the reaction [enkephalin, Ser(2), Leu(5), Thr(6)- binds to OPRD1 protein]; Copper inhibits the reaction [enkephalin, Ser(2), Leu(5), Thr(6)- binds to OPRD1 protein]; Mercury inhibits the reaction [enkephalin, Ser(2), Leu(5), Thr(6)- binds to OPRD1 protein]

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960

enalapril

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ABCC4 protein results in increased transport of Enalapril

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

angiotensin I converting enzyme

decreases activity
multiple interactions
increases expression

Enalapril results in decreased activity of ACE protein
Enalapril inhibits the reaction [Dexamethasone results in increased expression of ACE protein]; Enalapril inhibits the reaction [diisononyl phthalate promotes the reaction [Dexamethasone results in increased expression of ACE protein]]; Enalapril inhibits the reaction [Formaldehyde results in increased expression of ACE protein]
ACE gene polymorphism affects the susceptibility to [Enalapril co-treated with Sodium Chloride]; ACE gene polymorphism inhibits the reaction [[Enalapril co-treated with Sodium Chloride] results in increased susceptibility to AGT protein modified form]
Enalapril results in increased expression of ACE mRNA
Enalapril inhibits the reaction [Streptozocin results in increased expression of ACE mRNA]; Enalapril inhibits the reaction [Streptozocin results in increased expression of ACE protein]; Enalapril promotes the reaction [Folic Acid results in increased expression of ACE mRNA]

PMID:15728788 PMID:15816410 PMID:20679179 PMID:20829712 PMID:23733546 More...

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

actin alpha 2, smooth muscle

decreases expression

Enalapril results in decreased expression of ACTA2 protein

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

activin A receptor like type 1

decreases expression

Enalapril results in decreased expression of ACVRL1 protein

NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591

G

adiponectin, C1Q and collagen domain containing

increases expression

Enalapril results in increased expression of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adrenoceptor beta 1

increases expression

Enalapril results in increased expression of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

angiotensinogen

decreases activity
affects response to substance
increases expression
decreases response to substance
multiple interactions
decreases expression

Enalapril results in decreased activity of AGT protein modified form
AGT gene alternative form affects the susceptibility to Enalapril; AGT protein polymorphism affects the susceptibility to Enalapril
Enalapril results in increased expression of AGT mRNA
Enalapril results in decreased susceptibility to AGT protein modified form
Enalapril affects the reaction [chymostatin results in decreased susceptibility to AGT protein modified form]; Enalapril inhibits the reaction [Cyclosporine results in increased expression of AGT protein]; Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased expression of AGT protein]
Enalapril results in decreased expression of AGT protein modified form
[Enalapril co-treated with Sodium Chloride] results in increased susceptibility to AGT protein modified form; ACE gene polymorphism inhibits the reaction [[Enalapril co-treated with Sodium Chloride] results in increased susceptibility to AGT protein modified form]; Enalapril inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone]
Enalapril results in decreased expression of AGT mRNA

PMID:1330361 PMID:2474097 PMID:6319675 PMID:12003776 PMID:12911327 More...

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

increases expression
multiple interactions
decreases expression
affects expression

Enalapril results in increased expression of AGTR1A mRNA
Enalapril inhibits the reaction [Dexamethasone results in increased expression of AGTR1 protein]; Enalapril inhibits the reaction [diisononyl phthalate promotes the reaction [Dexamethasone results in increased expression of AGTR1 protein]]; Enalapril inhibits the reaction [Formaldehyde results in increased expression of AGTR1 protein]
Enalapril results in decreased expression of AGTR1A mRNA
Enalapril inhibits the reaction [Cyclosporine results in decreased expression of AGTR1A mRNA]
Enalapril affects the expression of AGTR1A mRNA

PMID:14659064 PMID:18403896 PMID:18765277 PMID:18796534 PMID:30940551 More...

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

angiotensin II receptor, type 2

increases expression
decreases expression

Enalapril results in increased expression of AGTR2 mRNA
Enalapril results in decreased expression of AGTR2 mRNA

PMID:9740612 PMID:18403896 PMID:18765277

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

AKT serine/threonine kinase 1

multiple interactions

Enalapril promotes the reaction [Isoproterenol results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

alkaline phosphatase, biomineralization associated

multiple interactions

Enalapril inhibits the reaction [Corticosterone results in decreased expression of ALPL mRNA]; Enalapril inhibits the reaction [Ethanol results in decreased expression of ALPL mRNA]

PMID:30423288 PMID:31887396

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

angiogenin

decreases expression

Enalapril results in decreased expression of ANG protein

NCBI chr15:24,312,711...24,323,361

G

angiopoietin 2

multiple interactions

Enalapril inhibits the reaction [Streptozocin results in increased expression of ANGPT2 mRNA]

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

apolipoprotein E

multiple interactions

[Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin co-treated with Valsartan] results in decreased expression of APOE protein
Enalapril inhibits the reaction [APOE gene mutant form results in decreased abundance of Antioxidants]; Enalapril inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]

PMID:19603250 PMID:25037058

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

activating transcription factor 2

increases expression

Enalapril results in increased expression of ATF2 protein

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

ATPase Na+/K+ transporting subunit alpha 2

increases expression

Enalapril results in increased expression of ATP1A2 mRNA; Enalapril results in increased expression of ATP1A2 protein

NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544

G

ATPase Na+/K+ transporting subunit alpha 3

decreases expression

Enalapril results in decreased expression of ATP1A3 mRNA; Enalapril results in decreased expression of ATP1A3 protein

NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918

G

arginine vasopressin

multiple interactions

Enalapril promotes the reaction [Dexamethasone results in increased activity of AVP protein]

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2 associated X, apoptosis regulator

decreases expression

Enalapril results in decreased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases expression
multiple interactions

Enalapril results in increased expression of BCL2 protein
Enalapril inhibits the reaction [Isoproterenol results in decreased expression of BCL2 protein]

PMID:21153712 PMID:30623541

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bradykinin receptor B1

increases expression
multiple interactions

Enalapril results in increased expression of BDKRB1 mRNA
[kallidin, des-Arg(10)- results in decreased activity of BDKRB1 protein] which results in decreased susceptibility to Enalapril

PMID:18796534 PMID:21430409

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

bradykinin receptor B2

increases expression

Enalapril results in increased expression of BDKRB2 mRNA; Enalapril results in increased expression of BDKRB2 protein

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

beclin 1

increases expression

Enalapril results in increased expression of BECN1 protein

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

bone gamma-carboxyglutamate protein

multiple interactions

Enalapril inhibits the reaction [Corticosterone results in decreased expression of BGLAP mRNA]; Enalapril inhibits the reaction [Ethanol results in decreased expression of BGLAP mRNA]

PMID:30423288 PMID:31887396

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

carbonic anhydrase 2

decreases activity

Enalapril results in decreased activity of CA2 protein

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

caspase 3

decreases activity
multiple interactions

Enalapril results in decreased activity of CASP3 protein
Enalapril inhibits the reaction [Isoproterenol results in increased expression of CASP3 protein]

PMID:21153712 PMID:30623541

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

decreases activity

Enalapril results in decreased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

increases activity
multiple interactions

Enalapril results in increased activity of CAT protein
Enalapril inhibits the reaction [Isoproterenol results in decreased expression of CAT protein]

PMID:12124199 PMID:30623541

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions
decreases expression

[paricalcitol co-treated with Enalapril] results in decreased expression of CCL2 protein
Enalapril inhibits the reaction [sodium arsenite results in increased secretion of CCL2 protein]
Enalapril results in decreased expression of CCL2 protein
Enalapril results in decreased expression of CCL2 mRNA

PMID:10925121 PMID:17513326 PMID:19627010 PMID:20720404 PMID:25037058 More...

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cellular communication network factor 2

decreases expression
multiple interactions

Enalapril results in decreased expression of CCN2 mRNA; Enalapril results in decreased expression of CCN2 protein
Enalapril inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]

PMID:18812665 PMID:19349682 PMID:21416479 PMID:25037058

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

chymotrypsin like elastase 2A

decreases expression

Enalapril results in decreased expression of CELA2A mRNA

NCBI chr 5:154,126,879...154,136,630
Ensembl chr 5:154,126,878...154,136,632

G

collectrin, amino acid transport regulator

decreases expression

Enalapril results in decreased expression of CLTRN mRNA; Enalapril results in decreased expression of CLTRN protein

NCBI chr X:30,361,967...30,395,264
Ensembl chr X:30,361,967...30,395,349

G

clusterin

decreases expression

Enalapril results in decreased expression of CLU protein

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

chymase 1

decreases expression

Enalapril results in decreased expression of CMA1 mRNA

NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233

G

collagen type I alpha 1 chain

multiple interactions

Enalapril inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

decreases expression
increases expression

Enalapril results in decreased expression of COL3A1 mRNA
Enalapril results in increased expression of COL3A1 mRNA

PMID:17164399 PMID:25037058

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type IV alpha 1 chain

multiple interactions
decreases expression

[eplerenone co-treated with Enalapril] inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]; [eplerenone co-treated with Enalapril] results in decreased expression of COL4A1 mRNA; [eplerenone co-treated with Enalapril] results in decreased expression of COL4A1 protein; Enalapril inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]; Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of COL4A1 mRNA]
Enalapril results in decreased expression of COL4A1 mRNA; Enalapril results in decreased expression of COL4A1 protein

PMID:9175058 PMID:18682491

NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412

G

citrate synthase

increases activity

Enalapril results in increased activity of CS protein

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

cytochrome b-245 alpha chain

multiple interactions
decreases expression

[paricalcitol co-treated with Enalapril] results in decreased expression of CYBA protein
Enalapril results in decreased expression of CYBA protein

PMID:20720404 PMID:25037058

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome c, somatic

affects localization

Enalapril affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

Enalapril inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

endothelin 1

multiple interactions

Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDN1 mRNA]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endoglin

multiple interactions

[Enalapril co-treated with paricalcitol] results in decreased expression of ENG mRNA

NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230

G

erythropoietin

decreases expression
multiple interactions

Enalapril results in decreased expression of EPO protein
Enalapril inhibits the reaction [Streptozocin results in increased expression of EPO mRNA]

PMID:2474097 PMID:9434678 PMID:19958114

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

erythropoietin receptor

multiple interactions

Enalapril inhibits the reaction [Streptozocin results in increased expression of EPOR mRNA]; Enalapril inhibits the reaction [Streptozocin results in increased expression of EPOR protein]

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

coagulation factor III, tissue factor

decreases expression
multiple interactions

Enalapril results in decreased expression of F3 protein
Enalapril inhibits the reaction [[Shiga Toxin 1 co-treated with TNF protein] results in increased activity of F3 protein]

PMID:18060435 PMID:22188725

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

Fas ligand

decreases expression

Enalapril results in decreased expression of FASLG mRNA

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

growth hormone 1

increases response to substance

GH1 protein results in increased susceptibility to Enalapril

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

gap junction protein, alpha 5

multiple interactions

GJA5 affects the reaction [Enalapril results in increased secretion of REN protein]

NCBI chr 2:184,602,407...184,621,952
Ensembl chr 2:184,564,475...184,621,952

G

gap junction protein, gamma 1

multiple interactions

GJC1 affects the reaction [Enalapril results in increased secretion of REN protein]

NCBI chr10:87,758,192...87,785,443
Ensembl chr10:87,760,528...87,785,867

G

glycogen synthase kinase 3 beta

multiple interactions

Enalapril inhibits the reaction [Isoproterenol results in decreased phosphorylation of GSK3B protein]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

hyaluronan synthase 2

increases expression

Enalapril results in increased expression of HAS2 mRNA

NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933

G

high mobility group box 1

multiple interactions

Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased expression of HMGB1 protein]
Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased secretion of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

increases expression

Enalapril results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hyaluronidase 1

decreases expression

Enalapril results in decreased expression of HYAL1 mRNA; Enalapril results in decreased expression of HYAL1 protein

NCBI chr 8:108,250,668...108,254,519
Ensembl chr 8:108,250,667...108,260,210

G

intercellular adhesion molecule 1

decreases expression
multiple interactions

Enalapril results in decreased expression of ICAM1 protein
Enalapril inhibits the reaction [sodium arsenite results in increased secretion of ICAM1 protein modified form]
[Enalapril co-treated with paricalcitol] results in decreased expression of ICAM1 mRNA
Enalapril results in decreased expression of ICAM1 protein modified form

PMID:14716214 PMID:17347482 PMID:25037058 PMID:28973481

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

insulin-like growth factor 1

affects expression
decreases expression

Enalapril affects the expression of IGF1 protein
Enalapril results in decreased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein 1

increases expression

Enalapril results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 1 alpha

multiple interactions

Enalapril inhibits the reaction [IL1A protein results in increased expression of VEGFA mRNA]; Enalapril inhibits the reaction [IL1A protein results in increased expression of VEGFA protein]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
decreases expression

Enalapril inhibits the reaction [Acrolein results in increased expression of IL1B mRNA]; Enalapril inhibits the reaction [Acrolein results in increased expression of IL1B protein]; Enalapril inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA]
Enalapril results in decreased expression of IL1B mRNA

PMID:17167242 PMID:21265103 PMID:25037058

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
affects response to substance

Enalapril inhibits the reaction [Acrolein results in increased expression of IL6 mRNA]; Enalapril inhibits the reaction [Acrolein results in increased expression of IL6 protein]; Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased expression of IL6 protein]; Enalapril inhibits the reaction [Isoproterenol results in increased expression of IL6 protein]; Enalapril inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA]
Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased secretion of IL6 protein]
IL6 gene polymorphism affects the susceptibility to Enalapril

PMID:15342284 PMID:17167242 PMID:19114890 PMID:21265103 PMID:30623541

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin-1 receptor-associated kinase 1

multiple interactions

[Atorvastatin co-treated with Enalapril] results in decreased expression of IRAK1 mRNA

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

integrin subunit alpha 2

decreases expression

Enalapril results in decreased expression of ITGA2 mRNA

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

kinase insert domain receptor

multiple interactions

Enalapril inhibits the reaction [Cyclosporine results in increased expression of KDR mRNA]

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

kininogen 1

increases response to substance

Enalapril results in increased susceptibility to KNG1 protein modified form

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

laminin subunit beta 1

multiple interactions

Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB1 mRNA]

NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585

G

laminin subunit beta 2

multiple interactions

Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB2 mRNA]

NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549

G

leptin

increases response to substance

LEP protein results in increased susceptibility to Enalapril

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen-activated protein kinase 9

increases expression
increases phosphorylation

Enalapril results in increased expression of MAPK9 mRNA; Enalapril results in increased expression of MAPK9 protein
Enalapril results in increased phosphorylation of MAPK9 protein

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

mitofusin 2

increases expression

Enalapril results in increased expression of MFN2 protein

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

microRNA 146a

multiple interactions

[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146A

NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610

G

microRNA 146b

multiple interactions

[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146B

NCBI chr 1:245,203,438...245,203,525
Ensembl chr 1:245,203,438...245,203,525

G

matrix metallopeptidase 3

decreases expression

Enalapril results in decreased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961